I will look into that.  However, since their has been new assets in the form of patents and patent agreements, they do have a material impact on BMSN.  Keep in mind that if the only qualifier were income, many holding companies would have zero value as their are plenty of subsidiaries reporting no income.  heck, Regen is not expected to provide income in the classic sense for quite some time (late next year at the earliest in my estimation).  The biz plan was to move IP along the approval process and then sell the equity to a major pharma.  This would not be reported as income until after the sale was closed.  So, if income were the qualifier, it would leave many shell companies in the lurch and would rightly scare away future investors.  As this is not the case, I am doubtful of your supposition. However, I will look into and report back what I find.

DSUS -